Media headlines about Diffusion Pharmaceuticals (NASDAQ:DFFN) have trended somewhat positive on Sunday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Diffusion Pharmaceuticals earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the company an impact score of 47.0121249947792 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Diffusion Pharmaceuticals (NASDAQ DFFN) opened at $1.42 on Friday. Diffusion Pharmaceuticals has a 52 week low of $1.06 and a 52 week high of $6.93.
ILLEGAL ACTIVITY WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/14/diffusion-pharmaceuticals-dffn-receiving-somewhat-favorable-press-coverage-analysis-shows.html.
About Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc, formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments.
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.